Skip to content

Study · Animal study (in vivo) · mouse · 2015

7 results

Evaluation of thymosin α 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis.

King RS, Tuthill C

Expert opinion on biological therapy2 Feb 2015Cited by 18 (Europe PMC)

PMID25643200 (opens in a new tab)DOI10.1517/14712598.2015.1008446 (opens in a new tab)PepBankPUB-25643200
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with B16 lung metastases, thymosin alpha‑1 alone reduced the number of metastases by 32%.

    In plain wordsIn mice with lung metastases from melanoma, thymosin alpha‑1 alone reduced the number of metastases.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseLung metastases in B16 lung metastasis model
    Study

    mousen: not reported in source

    B16 lung metastasis model
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    Metastases decrease
    32%
    Ta1 alone

    Source sentences

    Summary
    In the lung metastasis model, Ta1 treatment alone led to a 32% decrease in metastases (p < 0.05).
    1 context sentence
    Summary · context
    Three nonclinical murine models were utilized, including: i) a lung metastasis B16 model; ii) a B16-based tumor growth model; and iii) a cecal-ligation and puncture (CLP) sepsis model.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with B16 tumors, thymosin alpha‑1 reduced tumor growth significantly, by 34% to 46% depending on the dose.

    In plain wordsIn mice with melanoma tumors, thymosin alpha‑1 reduced tumor growth, with a larger effect at some doses.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseTumor growth in B16 tumor growth model
    Study

    mousen: not reported in source

    B16 tumor growth model
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    Tumor growth decrease
    34 to 46%
    depending on Ta1 dose

    Source sentences

    Summary
    In the tumor growth model, significant decreases in tumor growth were seen: 34% (p = 0.015) to 46% (p = 0.001) depending on the Ta1 dose.
    1 context sentence
    Summary · context
    Three nonclinical murine models were utilized, including: i) a lung metastasis B16 model; ii) a B16-based tumor growth model; and iii) a cecal-ligation and puncture (CLP) sepsis model.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cecal-ligation and puncture sepsis, thymosin alpha‑1 showed a positive trend towards increased survival, with no significant effect stated.

    In plain wordsIn mice with sepsis, thymosin alpha‑1 showed a trend towards better survival.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeSurvival in CLP sepsis model
    Study

    mousen: not reported in source

    Cecal-ligation and puncture sepsis model
    Outcome group
    Mortality · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Ta1 treatment showed a positive trend towards increased survival and decreased bacterial load.
    1 context sentence
    Summary · context
    Three nonclinical murine models were utilized, including: i) a lung metastasis B16 model; ii) a B16-based tumor growth model; and iii) a cecal-ligation and puncture (CLP) sepsis model.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cecal-ligation and puncture sepsis, thymosin alpha‑1 showed a positive trend towards decreased bacterial load, with no significant effect stated.

    In plain wordsIn mice with sepsis, thymosin alpha‑1 showed a trend towards a lower bacterial load.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeBacterial load in CLP sepsis model
    Study

    mousen: not reported in source

    Cecal-ligation and puncture sepsis model
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Ta1 treatment showed a positive trend towards increased survival and decreased bacterial load.
    1 context sentence
    Summary · context
    Three nonclinical murine models were utilized, including: i) a lung metastasis B16 model; ii) a B16-based tumor growth model; and iii) a cecal-ligation and puncture (CLP) sepsis model.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mice with cecal-ligation and puncture sepsis, thymosin alpha‑1 appeared to affect the levels of some biomarkers; the direction is not stated.

    In plain wordsIn mice with sepsis, thymosin alpha‑1 appeared to change the levels of some biomarkers.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedBiomarker levels in CLP sepsis model
    Study

    mousen: not reported in source

    Cecal-ligation and puncture sepsis model
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this CLP model, Ta1 also appeared to have an effect on the levels of some biomarkers.
    1 context sentence
    Summary · context
    Three nonclinical murine models were utilized, including: i) a lung metastasis B16 model; ii) a B16-based tumor growth model; and iii) a cecal-ligation and puncture (CLP) sepsis model.
  6. 06AnimalAnimal study (in vivo)Safety outcome

    In the three mouse models, thymosin alpha‑1 showed no evidence of toxicity.

    In plain wordsIn mice, thymosin alpha‑1 showed no evidence of toxicity in these three models.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeToxicity across the three models
    Study

    mousen: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    with no evidence of toxicity.
    1 context sentence
    Summary · context
    Three nonclinical murine models were utilized, including: i) a lung metastasis B16 model; ii) a B16-based tumor growth model; and iii) a cecal-ligation and puncture (CLP) sepsis model.

Studies that did not test the peptide alone1

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 07AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In mice with B16 lung metastases, thymosin alpha‑1 combined with an anti-PD-1 antibody gave significantly fewer metastases than vehicle.

    In plain wordsIn mice with lung metastases from melanoma, thymosin alpha‑1 together with an anti-PD-1 antibody gave fewer metastases than vehicle.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseLung metastases with Ta1 plus anti-PD-1 antibody
    Study

    mousen: not reported in source

    B16 lung metastasis model
    Comparator
    Vehicle
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Additionally, combinations of Ta1 and an anti-PD-1 antibody led to significantly fewer metastases than vehicle.
    1 context sentence
    Summary · context
    Three nonclinical murine models were utilized, including: i) a lung metastasis B16 model; ii) a B16-based tumor growth model; and iii) a cecal-ligation and puncture (CLP) sepsis model.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

Active, not recruitingPhase 2NCT06056804

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Beijing Friendship Hospitaln = 203 Jan 2024 to est. 1 Jul 2027

Locally Advanced Rectal Cancer

Trial pageClinicalTrials.govUpdated 2 Apr 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.